ImmunityBio Achieves Manufacturing Breakthrough for NK Cell Therapy Platform with Scalable Production Process
核心洞察
ImmunityBio successfully established a scalable manufacturing pathway for its M-ceNK cell therapy, producing up to 5 billion highly pure NK cells from a single apheresis collection within 12 days.
The company completed Phase I safety studies across 74 subjects, demonstrating zero serious adverse events and successful cryopreservation of NK cells with retained cytotoxicity against multiple tumor types.
Preclinical data from the National Cancer Institute showed statistically significant tumor volume reductions in small cell lung cancer (搜索) models when M-ceNK cells were combined with ANKTIVA.
ImmunityBio has achieved a significant manufacturing milestone for its memory cytokine-enhanced natural killer (M-ceNK) cell therapy platform, successfully establishing a scalable production process that yields up to 5 billion highly pure NK cells from a single apheresis collection. The commercial-stage immunotherapy company announced completion of its NK2022 and NK2023 manufacturing engineering programs, which enrolled 74 subjects and demonstrated the safety and reproducibility of large-scale NK cell production.
Manufacturing Process Validation
The company's manufacturing validation programs evaluated 64 subjects across healthy donors and cancer patients, successfully completing apheresis collection without procedure-related serious adverse events (SAEs). The process demonstrated remarkable efficiency, producing finished dosage forms of M-ceNK cells within 12 days from apheresis and generating sufficient material for 8-10 therapeutic doses per patient.
"These data demonstrate that potent NK cell therapy can be manufactured at scale and administered safely, potentially offering a reliable autologous source of potent NK cells," said Patrick Soon-Shiong, MD, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. "The ability to generate up to 5 billion highly pure NK cells from a single apheresis collection, yielding up to 8-10 therapeutic doses within 12 days, opens the possibility of creating the 'World Bank of Natural Killer Cells', with NK cells able to be universally donated to any patient without HLA matching."
Among the 64 apheresis subjects, 10 cancer patients received their collected cells following ImmunityBio's NK cell enrichment process, with 23 total doses administered demonstrating successful repeat dosing and cryo-banking capabilities. Critically, no SAEs were reported in the cancer subjects during their treatment cycles.
Clinical Safety Profile
The Phase I QUILT-3.076 trial evaluated the combination of autologous M-ceNK cells with ANKTIVA (nogapendekin alfa inbakicept-pmln) in 10 patients with relapsed or refractory solid tumors. Patients received weekly intravenous M-ceNK infusions ranging from 0.25 to 0.75×10⁹ cells per dose, with up to 10 doses combined with subcutaneous ANKTIVA administered every two weeks.
The trial enrolled patients with various cancer types including breast (N=4), colon (N=1), duodenum (N=1), renal (N=1), pancreatic (N=1), rectal (N=1), and osteosarcoma (搜索) (N=1). All infusions were performed in an outpatient setting, with patients receiving between 2 to 5 treatment bags. The safety profile was notable for zero treatment-related adverse events of Grade 4 or 5 severity and zero instances of cytokine storm.
Preserved NK Cell Function Across Patient Populations
Post-collection immune profiling revealed preserved NK cell activity and phenotype in both healthy donors and cancer patients, including those with prior exposure to systemic therapy. NK cells derived from cancer patients demonstrated cytotoxic activity equivalent to healthy donor-derived NK cells against NK-resistant cell lines representing multiple histologies, including breast, Merkel cell, ovarian, chordoma, medulloblastoma, glioblastoma (搜索), adenocarcinoma, and lymphoma (搜索).
Preclinical Efficacy in Neuroendocrine Tumors
Additional translational evidence supporting the M-ceNK platform was presented by researchers from the National Cancer Institute at the AACR IO Annual Meeting 2026. The presentation reported the first in vivo efficacy data for the M-ceNK platform, showing statistically significant tumor volume reductions in two small cell lung cancer (搜索) (SCLC (搜索)) xenograft models when M-ceNK cells were combined with ANKTIVA (p<0.01 and p<0.001, respectively).
The treatment also significantly increased MHC-Class I (搜索) expression on residual tumor cells (p<0.0001), suggesting a dual mechanism of action involving direct NK cell-mediated tumor killing followed by conversion of residual tumors to a state potentially responsive to immune checkpoint inhibitors.
Addressing Unmet Medical Need in Neuroendocrine Cancers
The research identified a substantial patient population with unmet therapeutic need, as tissue microarray analysis demonstrated that 62% of neuroendocrine tumors (搜索) lack MHC-Class I (搜索) expression. This renders them resistant to T cell-based immunotherapies but vulnerable to NK cell-mediated killing through the missing-self recognition mechanism.
M-ceNK cells generated from healthy donor peripheral blood mononuclear cells expressed high levels of activating receptors, low levels of inhibitory receptors, and produced elevated interferon-gamma and granzyme B upon stimulation. In standardized cytotoxicity assays, M-ceNK cells demonstrated potent killing activity against the majority of tumor cell lines evaluated, with the greatest cytotoxic activity observed against neuroendocrine tumor models, including five SCLC (搜索) lines, four pulmonary carcinoid lines, and a large cell neuroendocrine carcinoma line.
AI-Driven Manufacturing Readiness
The company has established methods in readiness for manufacturing in AI-driven automated robotic systems (NANT Leonardo), positioning the platform for potential commercial-scale production. The combination of M-ceNK cells with ANKTIVA is mechanistically designed to leverage the IL-15 (搜索) superagonist activity of ANKTIVA to sustain in vivo M-ceNK proliferation and persistence following adoptive transfer.
ANKTIVA is a first-in-class IL-15 (搜索) agonist IgG1 fusion complex consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex mimics the natural biological properties of membrane-bound IL-15 receptor alpha, driving the activation and proliferation of NK cells with the generation of memory killer T cells that retain immune memory against tumor clones.